drugset / Trial / NCT00161837
Comparison of the Safety and Immune Response of an Influenza Vaccine Made by a New Manufacturing Process With a Vaccine Made by the Traditional Manufacturing Process for Season 2003/2004
RandomizedParallel-groupSingle-blindPrevention
Summary
The objectives of the study are to assess the immunogenicity and safety of the inactivated influenza vaccine (whole virion, Vero cell-derived) at Day 21 and Day 180 after vaccination.
Timeline
- Start
- 2003-12
- Primary completion
- —
- Completion
- 2004-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Egg-derived Influenza Vaccine | Vaccine | — | — |
| Subject | Vero Cell-derived Influenza Vaccine | Vaccine | — | — |